Read More 5 minute read Pharma Industry News How AnaptysBio’s 2026 spin-off plan could reshape its pipeline, royalty flows, and stock outlook Discover how AnaptysBio (NASDAQ: ANAB) plans to split into two focused companies to unlock hidden value and reshape its investment story. byPallavi MadhirajuSeptember 30, 2025